Exemplis Discimus 2005, 149(2):437-440
Mauris quam nulla, commodo quis, tincidunt in, laoreet vel, justo.
- Department of Venereology, Utapah Faculty Hospital, Republic of Yavin
Pellentesque justo magna, malesuada quis, pellentesque in, fringilla sit amet, tellus. Donec tortor nisi, commodo ac, dictum quis, mollis eget, mauris. Maecenas nulla lectus, tempor ac, tincidunt vel, mattis in, sem. Phasellus in massa cursus mauris porttitor condimentum. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Pellentesque justo magna, malesuada quis, pellentesque in, fringilla sit amet, tellus. Suspendisse nisi risus, tempor id, gravida nec, volutpat nec, dui.
Kµúčové slová: Morbi ipsum, Ut ligula, Fusce eu lacus, Proin malesuada, Sed eget nisl
Vloľený: June 10, 2005; Přijatý: September 25, 2005; Uverejnené: December 1, 2005
Referencie
- Stiborová M, Bieler CA, Wiessler M, Frei E. (2001) The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 62, 1675-84.
Prejs» k pôvodnému zdroju... 
Prejs» na PubMed... - Rigaudy P, Charcosset J-Y, Garbay-Jaureguiberry Ch, Jacquemin- Sablon A, Roques BP. (1989) Attempts to target antitumor drugs towards opioid receptor-rich mouse tumor cells with enkephalinellipticinium conjugates. Cancer Res 49,1836-42. Prejs» na PubMed...
- Devraj R, Barret JF, Fernandez JA, Katzenellenbogen JA, Cushman M. (1996) Design, synthesis and biological evaluation of ellipticineestradiol conjugates. J Med Chem 39, 3367-74. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Czerwinski G, Tarasova NI, Michejda CJ. (1998) Cytotoxic agents directed to peptide hormone receptors: Defining the requirements for a successful drug. Proc Natl Acad Sci USA 95,11520-5. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Auclair C. (1987) Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 259, 1-14. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Singh MP, Hill GC, Peoch D, Rayner, B, Inabach, JL, Lown JW. (1994) High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33, 10271-85. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Chu Y, Hsu MT. (1992) Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation. Nucleic Acids Res 20, 4033-8. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Monnot M, Mauffret O, Simon V, Lescot E, Psaume B, Saucier JM, Charra M, Belehradek JJr, Fermandjian S. (1991) DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem 25, 1820-9.
- Fossé P, René B, Charra M, Paoletti C, Saucier JM. (1992) Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol Pharmacol 42, 590-5. Prejs» na PubMed...
- Froelich-Ammon SJ, Patchan MW, Osheroff N, Thompson RB. (1995) Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem 270, 14998-5004. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Ohashi M, Sugikawa E, Nakanishi N. (1995) Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: A possible anticancer mechanism. Jpn J Cancer Res 86, 819-29. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Schwaller MA. Allard B, Lescot E and Moreau F. (1995) Protonophoric activity of ellipticine and isomers across the energy- transducing membrane of mitochondria. J Biol Chem 270, 22709-13. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E. (2003) Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 16, 38-47. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E. (2003) DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling. Int J Cancer 107, 885-90. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Stiborová M, Sejbal J, Bořek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudeček J, Wiessler M, Frei E. (2004) The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res 6, 8374-80. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Frei E, Bieler CA, Arlt VM, Wiessler M, Stiborová M. (2002) Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 64, 289-95. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S. (1999) Antitumor prodrug development using cytochrome P450 (CYP) mediated activation. Anti-Cancer Drug Design 14, 473-86. Prejs» na PubMed...
- Aimová D, Dlouhá T, Frei E, Stiborová M. Anticancer drug ellipticine acts as an inducer of CYP1A1/2 and potentiates its own pharmacological efficiency. In: Anzenbacher P and Hudecek J, editors. Cytochrome P450, Biochemistry, Biophysics and Drug Metabolism.. Bologna: Monduzzi Editore, 2003. p. 133-8.
- Stiborová M, Bořek-Dohalská L, Hodek P, Mráz J, Frei E. (2002) New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch Biochem Biophys 403, 41-9. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
- Bořek-Dohalská L, Hodek P, ©ulc M, Stiborová M. (2001) - Naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6. Chem-Biol Interact 138, 85-106. Prejs» k pôvodnému zdroju... Prejs» na PubMed...